Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons
Launched by MINAMIHANNO HOSPITAL · Jun 30, 2008
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
Benzodiazepines (BZDs) have been reported to cause negative impacts on motor as well as cognitive functions, which in turn could result in lethal incidents including falls especially in the elderly. This notwithstanding, few trials have evaluated a feasibility and benefits of discontinuing BZD-derivative hypnotics in a systematic manner in this frail population. In this study, we examined changes in motor and cognitive functions following the discontinuation of BZD hypnotics in older persons.
In this 8-week open-label study, subjects aged 50 or older who receive BZD as a hypnotic and do no...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female participants of any race or ethnicity with any psychiatric diagnosis
- • Age of 50 and older
- • Having been treated with an BZD-derivative hypnotic drug at a steady dose for at least 4 weeks
- Exclusion Criteria:
- • Incapacity to follow the instructions.
- • Unstable physical illness or significant neurological disorder
- • Psychiatric concerns raised by the physician of record regarding participation in the study.
About Minamihanno Hospital
Minamihanno Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust infrastructure for conducting research, the hospital collaborates with multidisciplinary teams of healthcare professionals. Minamihanno Hospital focuses on a range of therapeutic areas, aiming to enhance the understanding of disease mechanisms and develop novel treatment strategies. By fostering a patient-centered approach, the hospital ensures that clinical trials are conducted ethically and efficiently, ultimately contributing to the advancement of medical science and the betterment of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannou, Saitama, Japan
Patients applied
Trial Officials
Kenichi Tsunoda, MD
Principal Investigator
Minamihanno Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials